SUMMARY The aetiology of primary sclerosing cholangitis is unknown, but it is closely associated with ulcerative colitis. Serum anticolon antibodies, crossreacting with portal tracts, have been reported in patients with ulcerative colitis but no studies have been carried out in primary sclerosing cholangitis. The frequency of serum anticolon antibodies and portal tract antibodies have been measured in 24 patients with primary sclerosing cholangitis and ulcerative colitis; 15 patients with primary sclerosing cholangitis without ulcerative colitis; 77 patients without primary sclerosing cholangitis: 25 patients with Crohn's colitis; 10 patients with primary biliary cirrhosis; 22 patients with extrahepatic biliary obstruction and 20 normal controls. Serum anticolon and portal tract antibodies were detected using immunoperoxidase techniques on normal colon and obstructed human liver. Tissue typing was undertaken using a standard microcytotoxicity technique. The frequency of anticolon antibodies was markedly increased in primary sclerosing cholangitis patients with ulcerative colitis (62.5%) compared with patients with ulcerative colitis (17%) and Crohn's colitis (16%) (X2=17T9; p<0O001). The antibodies were almost entirely of IgG and IgA classes in all groups. Anticolon antibodies were not found in sera from any other group. Sera from eight of 15 patients with primary sclerosing cholangitis, ulcerative colitis and anticolon antibody reacted with portal tracts of human obstructed liver. This reaction was also seen in four of nine patients with ulcerative colitis and primary sclerosing cholangitis and in three of 15 patients with primary sclerosing cholangitis alone. Portal tract antibody was of IgG class and was not present in sera from any other groups. Unlike anticolon antibody, there was a close relationship between HLA-B8 phenotype and the portal tract antibody (p<0-02; X2=6.04).
SUMMARY The aetiology of primary sclerosing cholangitis is unknown, but it is closely associated with ulcerative colitis. Serum anticolon antibodies, crossreacting with portal tracts, have been reported in patients with ulcerative colitis but no studies have been carried out in primary sclerosing cholangitis. The frequency of serum anticolon antibodies and portal tract antibodies have been measured in 24 patients with primary sclerosing cholangitis and ulcerative colitis; 15 patients with primary sclerosing cholangitis without ulcerative colitis; 77 patients without primary sclerosing cholangitis: 25 patients with Crohn's colitis; 10 patients with primary biliary cirrhosis; 22 patients with extrahepatic biliary obstruction and 20 normal controls. Serum anticolon and portal tract antibodies were detected using immunoperoxidase techniques on normal colon and obstructed human liver. Tissue typing was undertaken using a standard microcytotoxicity technique. The frequency of anticolon antibodies was markedly increased in primary sclerosing cholangitis patients with ulcerative colitis (62.5%) compared with patients with ulcerative colitis (17%) and Crohn's colitis (16%) (X2=17T9; p<0O001). The antibodies were almost entirely of IgG and IgA classes in all groups. Anticolon antibodies were not found in sera from any other group. Sera from eight of The frequencies of anticolon antibodies in the groups of sera are shown in Table 1 ; Figure 1 illustrates the anticolon antibody using immunoperoxidase. In primary sclerosing cholangitis patients with ulcerative colitis there was a significant increase in the frequency of anticolon antibodies (62.5%) compared with ulcerative colitis patients (17%), and Crohn's disease (16%) (X =18.1; p<0.001). Anticolon antibodies were not detected in primary sclerosing cholangitis patients without ulcerative colitis, patients with primary biliary cirrhosis, patients with extrahepatic cholestasis, nor in normal controls.
In all groups tested, the anticolon antibodies were mainly of IgG and IgA classes ( Table 2 ). There was no difference in the distribution of immunoglobulin subclasses between ulcerative colitis patients with or without primary sclerosing cholangitis.
The HLA-B8 phenotype was found in 7/13 (54%) of primary sclerosing cholangitis patients with ulcerative colitis possessing a serum anticolon antibody and in six of nine (67%) of patients without anticolon antibody. 
Discussion
This study has shown that about 17% of patients with ulcerative colitis possess a circulating antibody to a colonic antigen. This frequency is similar to that reported previously using indirect immunofluorescence techniques." 12 Antibodies were mainly of IgG or IgA class, and only 15% of our patients with anticolon antibodies had an IgM antibody. In contrast, the only other study of immunoglobulin class in patients with ulcerative colitis and anticolon antibodies, found that IgM antibodies predominated. 3 There was a markedly increased frequency of circulating anticolon antibody in patients with primary sclerosing cholangitis in association with ulcerative colitis compared with patients with ulcerative colitis alone. Furthermore, anticolon antibodies were not found in patients with primary sclerosing cholangitis alone, in patients with primary biliary cirrhosis, nor in healthy control subjects. Despite the fact that 60% of the patients with primary sclerosing cholangitis and ulcerative colitis possessed the HLA-B8 phenotype, there was no correlation between HLA status and presence of anticolon antibodies.
Although the majority of patients with primary sclerosing cholangitis had extensive, mild colitis, the high frequency of anticolon antibodies is unlikely to be related to this, as no association has been found between anticolon antibodies and any of the One previous study claimed that anticolon antibody crossreacted with proliferating bile ducts.6 In the present study, sera from half of the patients with ulcerative colitis and primary sclerosing cholangitis reacted with portal tracts from obstructed liver. There was a poor correlation, however, with the presence of anticolon antibody and, in particular, serum from four patients reacted with portal tracts but were negative when repeatedly tested on colonic tissue. Furthermore, portal tract staining was seen in three patients with primary sclerosing cholangitis alone, all of whom were negative for anticolon antibody, and was present in two patients with ulcerative colitis alone (only one of whom possessed anticolon antibody). Moreover, there was a close relationship between the HLA-B8 phenotype and the antibody reacting with portal tracts, unlike the anticolon antibody. These results suggest that the antibody reacting with portal tracts in obstructed liver is distinct from the anticolon antibody. This was confirmed by the absorption studies which showed that the colonic staining could only be absorbed with colon, and that the liver staining could only be absorbed with liver.
Portal tract antibody appears to react with antigens only in proliferating bile ducts as no staining could be found using either normal or cirrhotic liver. Unfortunately, more precise identification of the localisation of the antigen was not possible as it was destroyed by fixation for electron microscopy (unpublished observations).
McFarlane et a1 have shown that lymphocytes of patients with primary sclerosing cholangitis are sensitised to a biliary antigen using a leucocyte migration inhibition test. Patients with primary biliary cirrhosis and chronic active hepatitis, however, may also show this hypersensitivity. Therefore it seems unlikely that the antigen involved is the same as that reacting with the portal tract antibodies found in the sera of our patients with primary sclerosing cholangitis, as the antibodies were not found in patients with primary biliary cirrhosis.
There is increasing evidence that immunological mechanisms may play an important role on the pathogenesis of primary sclerosing cholangitis.7 8 15 16 We have described previously3 9 and confirmed in this study that there is an increased prevalence of HLA-B8 in primary sclerosing cholangitis patients with and without ulcerative colitis. The presence of HLA-B8 has been associated with a number of organ specific autoimmune diseases such as Type I diabetes mellitus, 'lupoid' chronic active hepatitis, myasthenia gravis, and thyrotoxicosis. 17 These diseases are characterised by the production of autoantibodies which in some cases probably play an important role in pathogenesis. '8 19 Further studies are needed to determine the significance of anticolon and portal tract antibodies in the pathogenesis of primary sclerosing cholangitis.
In conclusion, patients with primary sclerosing cholangitis frequently possess circulating antibody to obstructed portal tracts, which is closely related to the HLA-B8 phenotype. In the majority of primary sclerosing cholangitis patients with ulcerative colitis, an antibody reacting to colonic antigens is also present and is significantly more frequent than in patients with ulcerative colitis alone. This anticolon antibody is not associated with HLA-B8. The liver and colonic antigens, in contrast with a previous report,6 do not crossreact.
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